MAOB
- Known as:
- MAOB
- Catalog number:
- Y213506
- Product Quantity:
- 200ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- MAOB
Related genes to: MAOB
- Gene:
- MAOB NIH gene
- Name:
- monoamine oxidase B
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- Xp11.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2016-10-05
Related products to: MAOB
Related articles to: MAOB
- This study aimed to predict the pharmacological mechanisms of Wenjing Tongluo Powder (WTP) in relieving post-laparoscopic shoulder pain (PLSP) using network pharmacology, and to provide prioritized candidate targets and pathways for future experimental validation. Active ingredients of WTP were screened from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform database using ADME criteria (oral bioavailability ≥ 30%, drug-likeness ≥ 0.18). Their potential targets were predicted via the SwissTargetPrediction database. PLSP-related targets were retrieved from disease databases (Online Mendelian Inheritance in Man, therapeutic target database, etc). The intersecting targets were analyzed through protein-protein interaction network construction (using STRING and Cytoscape) to identify hub genes, followed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. A total of 72 active ingredients and 546 potential targets of WTP were identified. 136 common targets intersected with PLSP-related targets. Protein-protein interaction network analysis highlighted COX-2, TNF-α, ESR1, EGFR, CASP3, BCL2, MAOA, MAOB, and PPARG as core targets. Gene Ontology analysis suggested involvement in processes like vascular regulation and G protein-coupled receptor activity. Kyoto Encyclopedia of Genes and Genomes enrichment analysis predicted that key pathways, including the calcium signaling pathway, cAMP signaling pathway, PI3K-Akt signaling pathway, and cGMP-PKG signaling pathway, may be crucial for the therapeutic effect. This network pharmacology study predicts that WTP may alleviate PLSP by modulating core targets (e.g., COX-2, TNF-α) and signaling pathways (e.g., PI3K-Akt). These findings provide a systemic mechanistic hypothesis and a focused direction for subsequent experimental studies to confirm the bioactivity and therapeutic relevance of these predictions. - Source: PubMed
Wei ZhaoyangYu HuiYu Shen'aoWang Yanru - Navigating the vast chemical space to identify potent therapeutic agents with optimal pharmacokinetic properties remains a formidable bottleneck in pharmaceutical development. While virtual screening is limited to the exploration of existing chemical libraries, de novo design offers a complementary approach by constructing novel chemical entities "from scratch," potentially accessing unexplored regions of the chemical universe. De novo design may lead to novel scaffolds or compounds when compared to searching the compounds from chemical libraries. This study introduces LigGen, a novel tool for de novo drug design (DNDD) that combines fragment-based drug design (FBDD) with recurrent neural networks (RNNs) and Monte Carlo Simulated Annealing (MCSA) to generate ligands for target proteins. LigGen is effective in generating novel and synthesizeable high-affinity ligands for various biological drug-targets. The efficacy of the tool is demonstrated by testing it on CrossDocked dataset, as well as by generating ligands for proteins Beta-secretase 1 (BACE1), Monoamine Oxidase B (MAO-B), and Acetylcholinesterase (AChE). LigGen presents a promising approach for advancing drug discovery, offering a robust platform for novel drug design. - Source: PubMed
Publication date: 2026/05/02
Yadav AnshulMurugan Natarajan Arul - Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder, affecting nearly 0.3% of the global population. Its pathology is primarily linked to dopaminergic neuronal loss in the substantia nigra, leading to hallmark motor impairments such as tremor, rigidity, and bradykinesia. A defining molecular feature of PD is the aberrant aggregation of α-synuclein, alongside dysregulation of proteins such as MAO-B, COMT, and LRRK2, which collectively contribute to disease progression. Within the current research, these proteins were designated as docking targets to explore the enzyme-modulating activity and the therapeutic promise of steroidal alkaloid candidates from the genus Fritillaria, a taxon long recognized in traditional medicine for its neuroprotective properties. Docking analyses revealed that among 70 compounds analysed, compound 65 exhibited strong MAO-B inhibitory activity (binding energy - 11 kcal/mol), compound 5 demonstrated pronounced COMT inhibition (- 9 kcal/mol), and compound 42 emerged as a promising dual-acting agent capable of targeting both enzymes. Favorable physicochemical attributes, including optimal lipophilicity, low polar surface area, and blood-brain barrier permeability, further support their suitability. These findings identify preliminary computational leads that warrant further experimental validation for potential future development. - Source: PubMed
Publication date: 2026/05/02
Farboodniay Jahromi Mohammad AliHashemi ShimaSadeghian SaraMovahedi MelikaPoustforoosh AlirezaSeradj Seyed HassanEmami Leila - Monoamine oxidase-B (MAO-B) inhibitors enhance endogenous dopaminergic activity and are well tolerated in initial therapy for Parkinson's disease (PD). However, clinical responsiveness differs and reliable predictors of treatment response are unavailable. - Source: PubMed
Publication date: 2026/04/27
Ito NaohitoOzawa JunnosukeKataoka KazuyukiMatsuoka KaoruNakanishi TatsuyaWada TakahideIshida AtsushiKanemoto MizukiOguchi TatsunoriTsuji MayumiKiuchi YujiMurakami Hidetomo - Neurodegenerative diseases (NDs) comprise a complex group of disorders characterized by the progressive loss of neurons in the CNS, resulting in cognitive and motor dysfunctions. Elucidating the molecular mechanisms underlying these diseases is essential to identify effective therapeutic strategies. The hallmarks of NDs include oxidative stress, mitochondrial dysfunction, neuroinflammation, and protein misfolding. Among the implicated molecular targets, monoamine oxidase B (MAO-B) plays a crucial role since it catalyzes the oxidative deamination of biogenic amines, such as amine neurotransmitters, and therefore plays an important role in the physiopathology of the brain and nervous system generating reactive oxygen species, so contributing to oxidative stress and inflammation. Elevated hMAO-B activity has been observed in Alzheimer's and Parkinson's disease, underscoring its potential as a therapeutic target for neuroprotection. Given the role of MAO-B activity in various molecular pathways related to neuroinflammatory and neurodegenerative processes that underlie the onset and progression of NDs, the development of more active and selective hMAO-B inhibitors could represent a promising avenue leading to safer and more effective therapies for Alzheimer's and Parkinson's disease. In this view, MAO-B inhibitors have long been investigated for their therapeutic potential in NDs. Building upon previous reviews, this updated overview focuses on the most recent advances from 2020 to today in the field of new small molecules hMAO-B inhibitors, highlighting results from preclinical studies. Attention is paid to the various classes of synthetic compounds that have emerged in recent years and, where available, the main structure-activity relationships (SARs) are discussed to provide insights into the molecular features responsible for hMAO-B inhibitory activity and selectivity. The aim is to provide researchers with a current perspective on the evolving landscape of hMAO-B inhibitor-based therapies for NDs. - Source: PubMed
Publication date: 2026/04/24
Salerno SilviaFabbri GiovanniDi Paolo Maria LuisaPiazzola FrancescoPiccarducci RebeccaCosta BarbaraCastellano SabrinaDalla Via LisaTaliani SabrinaDa Settimo Federico